- Home
- EHAB vs ATXS Comparison
EHAB vs ATXS Comparison
Compare EHAB & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHAB
- ATXS
- Stock Information
- Founded
- EHAB 2014
- ATXS 2008
- Country
- EHAB United States
- ATXS United States
- Employees
- EHAB N/A
- ATXS N/A
- Industry
- EHAB Hospital/Nursing Management
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- EHAB Health Care
- ATXS Health Care
- Exchange
- EHAB Nasdaq
- ATXS Nasdaq
- Market Cap
- EHAB 401.6M
- ATXS 401.2M
- IPO Year
- EHAB N/A
- ATXS 2015
- Fundamental
- Price
- EHAB $7.06
- ATXS $6.38
- Analyst Decision
- EHAB Buy
- ATXS Strong Buy
- Analyst Count
- EHAB 2
- ATXS 7
- Target Price
- EHAB $8.75
- ATXS $32.43
- AVG Volume (30 Days)
- EHAB 805.7K
- ATXS 351.5K
- Earning Date
- EHAB 08-05-2025
- ATXS 08-11-2025
- Dividend Yield
- EHAB N/A
- ATXS N/A
- EPS Growth
- EHAB N/A
- ATXS N/A
- EPS
- EHAB N/A
- ATXS N/A
- Revenue
- EHAB $1,032,300,000.00
- ATXS N/A
- Revenue This Year
- EHAB $4.66
- ATXS N/A
- Revenue Next Year
- EHAB $4.99
- ATXS N/A
- P/E Ratio
- EHAB N/A
- ATXS N/A
- Revenue Growth
- EHAB N/A
- ATXS N/A
- 52 Week Low
- EHAB $6.85
- ATXS $3.56
- 52 Week High
- EHAB $10.91
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- EHAB 21.36
- ATXS 71.44
- Support Level
- EHAB $7.07
- ATXS $5.60
- Resistance Level
- EHAB $7.54
- ATXS $6.89
- Average True Range (ATR)
- EHAB 0.36
- ATXS 0.35
- MACD
- EHAB -0.21
- ATXS 0.09
- Stochastic Oscillator
- EHAB 3.84
- ATXS 94.51
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.